Skip to content
Tirzepatide
- Alternative names
- Tirzepic, Mounjaro, Zepbound, LY3298176, GLP-1+GIP dual agonist
- CAS
- 2023788-19-2
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.52
- Amino acid sequence
- Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20 fatty diacid via γGlu-2xAEEA)-Ile-Ala-Gln-Aib-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
This product is intended exclusively for research and laboratory purposes (in vitro). It is not intended for diagnostic, therapeutic, food, cosmetic, veterinary or supplement use.
Purchases may be made only by adults. The buyer confirms appropriate knowledge and qualifications for safe handling of research chemicals.
Product description
What is tirzepatide?
Tirzepatide (LY3298176) is an innovative research peptide developed by Eli Lilly, representing a new class of incretin compounds. It is the first ever dual agonist of GIP and GLP-1 receptors (so-called "twincretin"), which simultaneously activates two key metabolic pathways: the glucose-dependent insulinotropic peptide (GIP) receptor and the glucagon-like peptide 1 (GLP-1) receptor.
This synthetic peptide consists of 39 amino acids and was designed based on the GIP skeleton with the addition of structural modifications. Due to acylation with the albumin-binding C20 fatty acid moiety, tirzepatide has an extended half-life of approximately 5 days, enabling once-weekly administration in clinical trials.
NEJM
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385(6):503-515. PubMed
Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness. Cardiovasc Diabetol. 2022;21:169. PubMed
Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PubMed
Cuevas-Ramos D, Mehta R. Triple Agonism Based Therapies for Obesity. Curr Diab Rep 2025;25(1):47. PMC
Samms RJ, Sloop KW. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes. 2025;74(8):1326-1333. Diabetes Journals
Tsoukas MA, Mantzoros CS. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2024;25:31-49. Taylor & Francis
Habib G, Ali A, Mohamed W, et al. The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis. Pharmaceuticals. 2025;18(5):668. MDPI
Tan B, Pan XH, Chew HSJ, et al. Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis. Diabetologia. 2023;66:1866-1885. PMC
Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201-223. PubMed
